Percutaneous Coronary Intervention

According to an analysis in JACC: Cardiovascular Interventions, the results of the ISCHEMIA trial of invasive vs. conservative treatment of stable ischemic heart disease may only be applicable to one-third of the real-world PCI population.

The FDA has classified Datascope/Getinge/Maquet’s recall of two intra-aortic balloon pumps for patients undergoing surgery as Class 1, the most serious type of recall.

A comprehensive STEMI protocol led to reductions in sex disparities in guideline-directed medical therapy, door-to-balloon time, in-hospital mortality and ischemic in-hospital events, according to new data.

Long-term ticagrelor monotherapy after PCI lowered risk for bleeding compared with 1-year dual antiplatelet therapy followed by 1-year aspirin monotherapy in patients with ACS, but not for those with CAD.

The FDA has identified Cordis’ recall of its angiographic catheter with radiopaque marker bands as Class I, the most serious type of recall.

Dual antiplatelet therapy for 1 month vs. 3 or more months in patients at high bleeding risk who had PCI with a biodegradable-polymer sirolimus-eluting stent (Ultimaster, Terumo).

September is Peripheral Artery Disease awareness month; therefore, Healio and Cardiology Today have compiled a list of recent updates in PAD research and treatment.

Despite fewer bleeding events, 1-month dual antiplatelet therapy with clopidogrel failed to prove noninferiority vs. 12-month DAPT after PCI and stent implantation for ACS, according to a presenter.

In patients at high bleeding risk, dual antiplatelet therapy for 1 month after PCI lowered bleeding rates and was noninferior for ischemic events compared with 3-month DAPT, according to results of the MASTER DAPT trial.

For patients with STEMI and multivessel CAD, complete revascularization reduced major CV events regardless of whether the primary mode of reperfusion was pharmacoinvasive or primary PCI, according to new data from the COMPLETE trial.